Efficacy of Subconjunctival Bevacizumab Injection after Pterygium Excision with Limbal Conjunctival Autograft in Recurred Pterygium

Abstract

Purpose: To evaluate the efficacy and safety of subconjunctival bevacizumab injection after pterygium excision with limbal conjunctival autograft and limbal fixation suture in recurred pterygium.Methods: We retrospectively reviewed the medical records of 9 patients (11 eyes) who received subconjunctival bevacizumab injection after pterygium excision with limbal conjunctival autograft and limbal fixation suture for recurred pterygium. All patients included in this study completed follow-up for at least 12 months. Demographic variables, postoperative clinical outcomes, and recurrence rate were analyzed. Recurrence of pterygium was evaluated at 12 months after surgery.Results: The study subjects comprised 5 male patients (5 eyes) and 4 female patients (6 eyes) with a mean age of 66.0 ± 13.0 years (range 43-78 years). Among the 11 eyes, no recurrence occurred after the follow-up period of 12 months.Conclusions: Subconjunctival bevacizumab injection after pterygium excision with limbal conjunctival autograft and limbal fixation suture appears to be an effective method of preventing the recurrence in recurred pterygium.